ALNY slides moderately
The stock is tracking a broader biotech sector decline with low volatility, suggesting orderly selling rather than panic, as Wall Street valuation cuts on the company compound with general risk-off sentiment in growth equities.
Sources: https://www.tipranks.com/news/catalyst/alnylam-stock-sinks-as-wall-street-slashes-valuation
Previous verdicts for ALNY
- AI Search: Analyst Commentary and Insider Filing Weigh on Alnylam Shares — 2026-10-13
- Target cut hits ALNY — 2026-10-01
- Analyst trims target — 2026-09-30
- RNAi sector buzz lifts ALNY — 2026-09-25
- ALNY slides moderately — 2026-09-09
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works